Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$486.62 USD

486.62
729,759

+1.86 (0.38%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $487.17 +0.55 (0.11%) 6:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (50 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Allscripts (MDRX) Q3 Earnings Meet, Revenues Beat Estimates

Allscripts' (MDRX) solid guidance for 2017 and a bullish long-term outlook are key highlights of Q3. The expansion in margins is encouraging.

    PerkinElmer (PKI) Beats Q3 Earnings, Updates '17 Guidance

    PerkinElmer (PKI) posted stellar third-quarter numbers from strong performance in particularly the Diagnostics segment.

      Pacific Biosciences (PACB) Q3 Loss Narrower Than Estimated

      Pacific Biosciences (PACB) witnesses solid contribution from the Instrument and Consumable revenue platforms. Consumable revenue growth was driven by higher installed base of instruments.

        DENTSPLY (XRAY) Earnings and Revenues Beat Estimates in Q3

        DENTSPLY SIRONA (XRAY) reported third-quarter 2017 adjusted earnings per share (EPS) of 70 cents, beating the Zacks Consensus Estimate by 4 cents.

          Align Technology (ALGN) Gains on InvisAlign, Competition Rife

          Align Technology (ALGN) continues to gain from strength in the InvisAlign space.

            DexCom (DXCM) Q3 Loss Narrower Than Expected, Revenues Meet

            DexCom (DXCM) rides high on Sensor and Transmitter revenues in Q3.

              Omnicell's Higher Investments Drive Costs, Competition Rife

              Omnicell (OMCL) continues to battle escalating costs emanating from several strategies adopted by the company. A tough competitive landscape also acts as a dampener.

                STERIS (STE) Q2 Earnings Miss & Revenues Beat, Margins Up

                STERIS (STE) witnessed year-over-year decline in Q2 revenues due to softness in Healthcare Products and the Healthcare Specialty Services segments.

                  Integra Gains on Global Growth, Hurricanes Hamper Business

                  Integra (IART) launches new regenerative products within its Orthopedics and Tissue Technologies segment. However, hurricanes in Q3 grossly affect the wound care and orthopedic procedures in Florida.

                    Becton, Dickinson (BDX) Beats on Q4 Earnings, Guidance Solid

                    Becton, Dickinson's (BDX) guidance for fiscal 2018 buoys optimism for investors. The company's Life Sciences business will be a key growth driver.

                      Wright Medical Group (WMGI) Q3 Earnings In Line, Sales Miss

                      Wright Medical (WMGI) posted loss as estimated in the third quarter on lower-than-expected sales.

                        Zimmer Biomet's (ZBH) Q3 Earnings Lag Estimates, View Down

                        Zimmer Biomet's (ZBH) declining revenue performance within most of the core segments, along with a rise in cost of products sold resulted in bottom line pressure in the third quarter.

                          Masimo (MASI) Beats on Q3 Earnings and Revenues, Raises View

                          Masimo (MASI) raises fiscal 2017 guidance. The year-over-year increase in both revenues and earnings encourages.

                            IDEXX Laboratories (IDXX) Q3 Earnings Beat, Revenues Miss

                            IDEXX Laboratories (IDXX) rides high on strength in Companion Animal Group business in Q3. Moreover, a raised guidance buoys optimism.

                              Ecolab (ECL) Beats Earnings & Revenues in Q3, Cuts 2017 View

                              Despite reporting solid third-quarter results, Ecolab (ECL) slashed its full-year earnings guidance, thanks to the hurricanes and the divestiture of the Equipment Care business segment.

                                Luminex (LMNX) Tops Q3 Earnings, Meets Revenue Estimates

                                Luminex's (LMNX) third quarter saw a strong top line, solid cash flow as well as profits in Q3. The company's Assay business is likely to drive growth over the long term.

                                  Omnicell (OMCL) Earnings Beat, Revenues Miss Estimates in Q3

                                  Omnicell (OMCL) witnessed year-over-year growth in revenues on the back of its Medication Adherence segment in Q3.

                                    Quality Systems (QSII) Beats on Earnings & Revenues in Q2

                                    Quality Systems' (QSII) solid total software, hardware revenues drove second-quarter earnings. A solid recurring revenue base is a key catalyst for the quarters to come.

                                      Abiomed (ABMD) Earnings and Revenues Beat Estimates in Q2

                                      Abiomed's (ABMD) strong performance in Impella heart pump boosted the company's second-quarter 2018 results.

                                        Integra LifeSciences (IART) Misses on Q3 Earnings & Revenues

                                        Integra LifeSciences' (IART) raised full-year 2017 revenue guidance buoys optimism.

                                          Align Technology (ALGN) Q3 Earnings Top on Invisalign Sales

                                          An extremely strong summer teen season drives Align Technology's (ALGN) Invisalign growth within the global teen market in the third quarter.

                                            Chemed (CHE) Beats on Q3 Earnings & Revenues, View Revised

                                            Chemed (CHE) rides high on its Roto-Rooter business in Q3

                                              ResMed (RMD) Q1 Earnings Top on Growth in All Business Lines

                                              ResMed (RMD) delivers a promising Q1 on the back of solid contributions from domestic and international businesses.

                                                Stryker (SYK) Earnings and Revenues Beat Estimates in Q3

                                                Stryker (SYK) posted strong numbers in the third quarter owing to higher revenues.

                                                  Cerner (CERN) Misses on Q3 Earnings, Bookings Decline Y/Y

                                                  Despite a tepid third quarter, Cerner's (CERN) bookings guidance for the fourth quarter is encouraging.